|
|
TRIF |
|
Vaxjo ID |
368 |
|
Vaccine Adjuvant Name |
TRIF |
|
Adjuvant VO ID |
VO_0005720
|
|
Description |
genetic adjuvant that induces Th1 response |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Second Host Species for Testing |
Pig |
|
Components |
Toll/interleukin-1 receptor domain-containing adaptor-inducing interferon-beta (TRIF) |
|
Preparation |
cDNA fragments encoding TLR adaptor molecules were amplified from parental plasmids by PCR and subcloned into the pGA vector |
|
Function |
Type: microbial derivative vaccine adjuvant. Target Receptor: Toll-like receptor 3 (TLR3) | Toll-like receptor 4 (TLR4). Induces Th1-biased immune profile. innate immune activation |
| References |
Takeshita et al., 2006: Takeshita F, Tanaka T, Matsuda T, Tozuka M, Kobiyama K, Saha S, Matsui K, Ishii KJ, Coban C, Akira S, Ishii N, Suzuki K, Klinman DM, Okuda K, Sasaki S. Toll-like receptor adaptor molecules enhance DNA-raised adaptive immune responses against influenza and tumors through activation of innate immunity. Journal of virology. 2006; 80(13); 6218-6224. [PubMed: 16775309].
Wan et al., 2010: Wan C, Yi L, Yang Z, Yang J, Shao H, Zhang C, Pan Z. The Toll-like receptor adaptor molecule TRIF enhances DNA vaccination against classical swine fever. Veterinary immunology and immunopathology. 2010; 137(1-2); 47-53. [PubMed: 20466439].
|
|
